Douglas P. Clark, MD
Chairman and CEO
BioMarker Strategies, LLC

Dr. Douglas P. Clark, the Chairman and CEO, is also an Associate Professor of Pathology & Oncology at The Johns Hopkins Medical Institutions, where he serves as the Director of the Division of Cytopathology.  He is a Board-Certified Anatomic Pathologist and Cytopathologist, with experience in oncology, microbiology and molecular diagnostics. He serves on the editorial board of Acta Cytologica, Cancer Cytopathology and Expert Review of Molecular Diagnostics. 

Dr. Clark has been at the forefront of efforts to integrate molecular biomarkers into the field of pathology.  At Johns Hopkins he has successfully developed a comprehensive molecular cytopathology program that serves as a vital resource to clinical trial development, particularly in the area of oncology.  This work has lead to numerous publications and a patent for a targeted therapy-related diagnostic test that has been licensed by BioMarker Strategies.  

Dr. Clark received his M.D. degree from The Johns Hopkins School of Medicine, Baltimore, Maryland, and his B.A. degree in Biochemistry and Molecular Biology from Northwestern University, Evanston, Illinois.  Dr. Clark will maintain positions at both Johns Hopkins and BioMarker Strategies in a plan that has been approved by the Johns Hopkins Conflict of Interest Committee. 

 
Scott Allocco
President
BioMarker Strategies, LLC



Scott Allocco, the President of BioMarker Strategies, has more than 13 years of health care and pharmaceutical industry experience including drug coverage and reimbursement issues for Medicare and Medicaid healthcare programs.  Prior to joining BioMarker Strategies as the full-time President in April of 2007, Mr. Allocco was the Vice-President of State Government Relations for Coventry Health Care, one of the nation’s largest health insurance and health care management companies.  Prior to obtaining that position, Mr. Allocco served for six years as the Vice-President for Business Development at First Health Services, now the Medicaid subsidiary of Coventry Health Care.  In this capacity, Mr. Allocco helped build First Health Services into the nation’s largest Pharmacy Benefits Administrator of Medicaid drug benefit programs—managing approximately $8 billion in drug spending in 2005.  He also helped the company to develop its First Health Premier Medicare Part D drug plan.

Prior to joining First Health Services, Allocco served as a Managing Director at Hill and Knowlton’s Washington DC Office, where he was a member of the company’s Health Care Practice Group.  He also served for four years as the Director of the Office of Government Affairs for the New Jersey Department of Health and Senior Services under the administration of former Governor Christine Todd Whitman. 

Given his experience with managed care, prescription drug management, pricing, reimbursement and health policy issues, he has been an invited speaker at numerous Medicaid, health policy and prescription drug management conferences. He graduated cum laude with a B.A. degree in Public Policy from Hamilton College in Clinton, N.Y.



 

Kathleen M. Murphy, PhD
Chief Science Officer (CSO)
BioMarker Strategies, LLC

Dr. Kathleen Murphy, the Chief Science Officer (CSO) of BioMarker Strategies, is also the Director of the Molecular Diagnostics Laboratory at Johns Hopkins Medical Institutions.  She is an Assistant Professor of Pathology and Oncology, and a Lecturer in the Graduate Program in Biotechnology at Johns Hopkins University.  Dr. Murphy’s work is primarily focused on molecular testing related to Oncology. 

At Johns Hopkins, she is involved in the development of molecular assays that are used for diagnostic and prognostic purposes, as well as monitoring residual disease following therapy.  Dr. Murphy is especially interested in identifying molecular abnormalities that can be targeted by novel therapeutic agents.  Dr. Murphy is also active in characterizing genetic mutations and polymorphisms that increase the risk for cancer and predict response to chemotherapeutic agents.  Finally, Dr. Murphy is interested in developing novel technologies which improve our ability to detect and quantify molecular targets.  Her work in this area at Johns Hopkins has lead to several patent applications (that are not owned by the Company).

Dr. Murphy’s training includes a B.S. in Medical Technology and a Ph.D. in Microbiology and Immunology.  She completed post-graduate training in the Mid-Atlantic Cancer Genetics Network and the Molecular Pathology Fellowship at Johns Hopkins University.  Dr. Murphy intends to maintain positions at both Johns Hopkins and BioMarker Strategies in a plan that has been approved by the Johns Hopkins Conflict of Interest Committee.

Dr. Adam Schayowitz is the Director of Research and Development at BioMarker Strategies, where he is responsible for the development of the SnapPath solid tumor cell processing system and business development issues. He earned his PhD in Pharmacology from the University of Maryland in 2008, where studied the mechanisms of resistance to hormonal therapy in breast and prostate cancer, including preclinical investigations of various signal transduction inhibitors in combination with hormonal therapy. His graduate research led to the development of multiple clinical trials in breast and prostate cancer. In 2007, he enrolled in the Life Sciences MBA program at The Carey Business School at Johns Hopkins University. From 2003-2005, Dr. Schayowitz worked as a research assistant for Defined Health, a NJ based pharmaceutical consulting firm focusing on market assessments, financial forecasting and strategic planning for the pharmaceutical and biotech industry. In this capacity, he performed secondary due diligence, market assessments, pipeline analyses and primary research across multiple therapeutic areas. Dr. Schayowitz graduated from Hamilton College in Clinton, NY with a B.A. in Neuroscience.

Dr. Scott Diamond, our bioengineering consultant and a member of our Scientific Advisory Committee, is the director of the Penn Center for Molecular Discovery at the University of Pennsylvania. Dr. Diamond researches biotechnologies in several key areas: endothelial mechanobiology, blood clot dissolving therapies, blood coagulation, non-viral gene therapy, proteomics, and high throughput drug discovery. He has produced over 80 publications and patents and has served on advisory committees to NSF, NIH, AHA, and NASA, and has consulted extensively for industry and government. Currently, Dr. Diamond is the Director of the Penn Biotechnology Masters Program, one of the largest in the country with more than 130 students. Dr. Diamond also serves as Associate Director of the Institute for Medicine and Engineering (IME).  He received his bachelor’s degree in chemical engineering in 1986 from Cornell University and his Ph.D. from Rice University in 1990. He holds the Arthur E. Humphrey Chair of Chemical and Biomolecular Engineering.

Dr. Manfred Scholz, Strategic Business Consultant, is the founder, president and principal consultant of Scholz Consulting Partners. He has extensive business development, licensing, operations, and strategic consulting experience in the biotechnology and diagnostic industries. He was President and Chief Operating Officer at Stem Cell Preservation Technologies, Vice President for Business Development at IQuum, Senior Director for Business Development at Large Scale Biology Corporation, Senior Consultant at Boston Biomedical Consultants, and held various system development and global marketing positions at Dade Behring. Prior, he held research positions at Massachusetts General Hospital, Harvard Medical School and Max Planck Institute for Biophysics. He researched and published in the fields of oncology, infectious diseases and in vivo imaging technologies. He received his Ph.D. in physics from Johann Wolfgang Goethe-University, Frankfurt, Germany and his M.B.A. from Babson College, Wellesley, Massachusetts.

Andrew Jiranek is General Counsel and Secretary of BioMarker Strategies, LLC, where he is responsible for general corporate legal matters and legal compliance.  He obtained his J.D. in 1987 from the College of William and Mary, Marshall-Wythe School of Law and his B.A. from Princeton University in 1984.  He is a Member of the Maryland, District of Columbia and Virginia bars. A practicing attorney based in Maryland, Mr. Jiranek has a broad-based business law practice representing corporations, partnerships and other business entities.

Tom Hoxie of Hoxie & Associates, in Millburn, New Jersey, advises the company on intellectual property matters.  The firm represents clients in patent matters relating to pharmaceuticals, chemicals and biotechnology, including multinational pharmaceutical companies and small biotechnology companies.  Tom Hoxie is the former head of Novartis's patent and trademark department in the United States. He also headed the intellectual property litigation function for Novartis and was deputy global head of pharmaceutical patents.  He also worked as a patent attorney in the pharmaceutical patent group at Sandoz (a predecessor company to Novartis) in Basel, Switzerland. 

Board of Directors— Biomarker Strategies expanded its Board of Directors in January of 2008 to include two outside members in addition to the three founding members- Dr. Douglas Clark, Scott Allocco, and Dr. Kathleen Murphy. They are:

• Karen Olson is the former President and CEO of Adhesives Research, Inc, a $150 million drug delivery and component supplier into the biotechnology, medical and pharmaceutical markets, global headquarter based in York, PA. Her personal business experience with the Fortune 500 companies in the pharmaceutical and diagnostic industry expands two decades. In addition to being an investor and shareholder in BioMarker Strategies, she has also been providing strategic business advice. She received her Executive MBA at Loyola College and Bachelors Degrees in Chemistry and Medical Technology from California Lutheran University.

• Jason Rubin president and founder of The Redstone Group, LLC, an independent public relations consulting firm serving biotechnology and pharmaceutical companies. He is an investor in BioMarker Strategies and serves as an advisor to the company on business strategy issues. He was previously the  senior communications officer for four biotechnology companies: Immunex, Cephalon, Centocor and Incyte.

Financial Accountants and Advisors

• Mark Rapson, CPA is a partner with KAWG&F, a regional accounting firm in Towson, MD, who also chairs the firm’s health and life sciences practice group.  Mr. Rapson advises the company on all financing and transactional structuring agreements.

• Rob Taylor, CPA, owns and operates Premier Business Solutions, the firm that manages the company's financial accounts.